# A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

> **NCT07660796** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 256 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** HCP1803-3
- **DRUG:** HCP1803-4
- **DRUG:** RLD2001-1
- **DRUG:** RLD2001-2

## Key facts

- **NCT ID:** NCT07660796
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-06
- **Primary completion:** 2027-10-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660796, "A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07660796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*